EMERALD ADVISERS, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
EMERALD ADVISERS, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$17,528,717
-31.2%
491,689
-10.9%
0.85%
-23.8%
Q2 2023$25,470,034
+29.6%
552,136
+12.6%
1.11%
+18.1%
Q1 2023$19,655,456
+23.1%
490,161
+42.2%
0.94%
+22.2%
Q4 2022$15,971,109
+11.1%
344,725
-0.7%
0.77%
+4.2%
Q3 2022$14,373,000
+19.7%
347,081
+72.5%
0.74%
+20.1%
Q2 2022$12,005,000
-26.2%
201,217
-10.2%
0.62%
-0.5%
Q1 2022$16,263,000
-18.0%
223,952
-5.0%
0.62%
-15.3%
Q4 2021$19,824,000
+12.1%
235,745
+20.2%
0.73%
+14.0%
Q3 2021$17,688,000
-11.8%
196,124
-6.7%
0.64%
-12.1%
Q2 2021$20,047,000
-22.9%
210,243
-7.9%
0.73%
-22.2%
Q1 2021$26,002,000
-17.2%
228,368
+0.7%
0.94%
-10.0%
Q4 2020$31,406,000
+32.3%
226,875
-32.8%
1.04%
+3.0%
Q4 2016$23,739,000
+23.9%
337,629
+25.1%
1.01%
+18.6%
Q3 2016$19,153,000
+168.8%
269,983
+288.0%
0.85%
+150.9%
Q2 2015$7,125,000
+69.4%
69,590
-1.6%
0.34%
+61.1%
Q1 2015$4,207,000
-18.2%
70,701
-39.7%
0.21%
-22.7%
Q4 2014$5,142,000
+112.7%
117,181
+174.4%
0.27%
+89.6%
Q3 2014$2,417,000
+39.1%
42,701
+10.3%
0.14%
+46.9%
Q2 2014$1,738,000
+33.3%
38,710
+45.1%
0.10%
+34.2%
Q1 2014$1,304,00026,6700.07%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders